Sharp Therapeutics Announces Filing of Amended and Restated Management Information Circular and New Annual Meeting Date

Rhea-AI Summary

Sharp Therapeutics (OTCQB: SHRXF) rescheduled its annual shareholder meeting to July 21, 2026 at 10:00 a.m. Toronto time and filed an amended and restated management information circular and notice of meeting.

The updates add disclosure for re-approval of the stock option plan, require shareholders to recast votes using new proxy forms, and set a proxy deadline of July 17, 2026. Materials are available on SEDAR+.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Shareholders Must Recast Their Votes to be Counted

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that its annual meeting of shareholders will be held at 10:00 a.m. (Toronto time) on July 21, 2026 (the "Meeting"), having been postponed from the initial meeting date of June 30, 2026.

The Company has filed an amended and restated notice of meeting (the "Amended and Restated NOM") and an amended and restated management information circular for the Meeting (the "Amended and Restated Circular") in order to give notice and disclosure in respect of the re-approval of the Company's stock option plan (the "Stock Option Plan"), which will be a matter of business considered at the Meeting.

The ordinary resolution re-approving the Stock Option Plan (the "Plan Resolution") was not included in the original management information circular dated May 27, 2026 or in the form of proxy or voting instruction form previously sent by the Company in connection with the Meeting. The Amended and Restated Circular includes the necessary information with respect to the Plan Resolution and the Stock Option Plan.

Shareholders should disregard the form of proxy or voting instruction form that was delivered to them with the prior notice of meeting and management information circular. A new form of proxy and voting instruction form will be provided to shareholders together with the Amended and Restated NOM and the Amended and Restated Circular.

For shareholders that have already provided voting instructions using their initial form of proxy, voting instruction form or control number, those instructions are no longer valid. Shareholders must provide new voting instructions for their shares to be voted, and should refer to the Amended and Restated Circular and new form of proxy or voting instruction form. Proxies must be received by 10:00 a.m. (Toronto time) on July 17, 2026, or not less than forty-eight (48) hours (excluding Saturdays, Sundays and holidays) before the time any adjourned Meeting is reconvened, or any postponed Meeting is convened.

Copies of the Amended and Restated NOM, the Amended and Restated Circular, the new form of proxy and the new voting instruction form will be available under the Company's profile on SEDAR+ at www.sedarplus.ca.

About Sharp Therapeutics Corp.

First-Choice Therapies for Genetic Diseases

Sharp Therapeutics is a preclinical-stage company developing first-choice small-molecule therapeutics for genetic diseases. The Company's small molecule discovery platform combines novel high throughput screening technologies, with compound libraries computational optimized based on the physics and biology of cellular trafficking defects and allosteric activation of proteins. The platform produces small molecule compounds that restore activity in mutated proteins giving the potential to treat genetic disorders with conventional pill-based medicines.

For additional information on Sharp, please visit: www.sharptx.com.

Sharp Therapeutics Corp.

Scott Sneddon, PhD, JD CEO/CSO
Email: scott@sharptx.com
Phone: (412) 206-5303

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect Sharp's current views and intentions with respect to future events, and current information available to Sharp, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Should any factor affect Sharp in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Sharp does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and Sharp undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303542

FAQ

When will Sharp Therapeutics (SHRXF) hold its 2026 annual shareholder meeting?

Sharp Therapeutics will hold its 2026 annual shareholder meeting on July 21, 2026, at 10:00 a.m. Toronto time. According to Sharp, the meeting was postponed from June 30, 2026, following the filing of amended and restated meeting materials.

Why did Sharp Therapeutics (SHRXF) file an amended and restated management information circular in June 2026?

Sharp filed an amended and restated circular to provide disclosure for re-approval of its stock option plan. According to Sharp, the original circular and proxy forms omitted the ordinary resolution re-approving the plan, so updated materials were required.

Do Sharp Therapeutics (SHRXF) shareholders need to recast their votes for the July 21, 2026 meeting?

Yes, all shareholders must recast their votes using the new proxy or voting instruction form. According to Sharp, any voting instructions submitted with the earlier forms or control numbers are no longer valid and will not be counted at the rescheduled meeting.

What is the proxy voting deadline for Sharp Therapeutics (SHRXF) 2026 annual meeting?

Proxies must be received by 10:00 a.m. Toronto time on July 17, 2026. According to Sharp, proxies are also due at least 48 hours before any adjourned or postponed meeting time, excluding Saturdays, Sundays, and holidays.

Where can investors find Sharp Therapeutics (SHRXF) amended and restated circular and new proxy forms?

Investors can access the amended and restated circular, notice of meeting, and new proxy forms on SEDAR+. According to Sharp, the documents are available under the company profile at www.sedarplus.ca for shareholder review before voting.

What is being voted on regarding Sharp Therapeutics (SHRXF) stock option plan in July 2026?

Shareholders will consider an ordinary resolution re-approving Sharp’s stock option plan at the July 21, 2026 meeting. According to Sharp, the amended circular now includes the required information about this Plan Resolution and the related equity compensation details.